Ideal Option, a national leader in outpatient medication-assisted treatment (MAT) for addiction to opioids, stimulants and other substances, has released its 2024 Annual Outcomes Report for Montana patients. Using advanced quadrupole time-of-flight (QTOF) mass spectrometry, Ideal Option identified fentanyl analogs with up to 70% lower potency than fentanyl, potentially contributing to a decline in overdose deaths.
The report aggregates data from over 1,500 Montana patients in 2024, detailing geographic and demographic profiles, treatment stages, medication adherence, and substance use trends based on lab specimens. Key findings highlight the success of office-based MAT, with 97% of patients in long-term recovery achieving sustained abstinence from opioids and stimulants. For Montana patients progressing from treatment initiation to maintenance in 2024, the report shows:
- 94% reduction in opioid use
- 84% reduction in stimulant use
In addition, Ideal Option analyzed over 11,000 new enrollment samples using QTOF testing to detect novel substances like fentanyl analogs and other psychoactive compounds not covered by standard clinical panels.
“We’re increasingly identifying fentanyl analogs, such as acetylfentanyl and fluorofentanyl, said Tim Kilgallon, CEO of Ideal Option. “Which are approximately 30% as potent as fentanyl.”
This shift in the drug supply may explain the national decline in overdose deaths. According to provisional data released by the U.S. Centers for Disease Control and Prevention (CDC), Montana saw a 7.6% reduction in overdose deaths in 2024 compared to 2023. While the decline in overdose deaths is encouraging, steady demand for treatment suggests that the lower potency of the drug supply has not reduced the availability or usage of addictive substances.
View the full Ideal Option 2024 Annual Patient Outcomes Report for Montana here: www.idealoption.com/patient-outcomes.
Ideal Option has helped more than 93,000 patients through a network of over 80 outpatient clinics across 9 states: Alaska, Arkansas, Idaho, Maryland, Montana, New Mexico, North Dakota, Oregon and Washington.
With no waitlists and most forms of insurance accepted, including Medicare and Medicaid, patients can typically get started on treatment for fentanyl, heroin, methamphetamine, alcohol or other substances within 1-3 business days.
Patients can make an appointment by calling 1-877-522-1275 or visiting www.idealoption.com.
Author: Staff
Our Staff account is used to publish submitted content. If you have content that was published under this account, and wish to have your name as author, please contact us at (406) 952-3021
